These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6160599)

  • 1. Depression vulnerability and 5-hydroxytryptophan prophylaxis.
    van Praag H; de Hann S
    Psychiatry Res; 1980 Sep; 3(1):75-83. PubMed ID: 6160599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprophylaxis of depressions. An attempt to compare lithium with 5-hydroxytryptophan.
    van Praag HM; de Haan S
    Acta Psychiatr Scand Suppl; 1981; 290():191-201. PubMed ID: 6164250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Harold E. Himwich Memorial Lecture. Significance of biochemical parameters in the diagnosis, treatment, and prevention of depressive disorders.
    Praag HM
    Biol Psychiatry; 1977 Feb; 12(1):101-31. PubMed ID: 300032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of depression with serotonin precursors.
    van Praag HM
    Biol Psychiatry; 1981 Mar; 16(3):291-310. PubMed ID: 6164407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central serotonin metabolism and frequency of depression.
    van Praag HM; de Haan S
    Psychiatry Res; 1979 Dec; 1(3):219-24. PubMed ID: 95233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin precursors in the treatment of depression.
    van Praag HM
    Adv Biochem Psychopharmacol; 1982; 34():259-86. PubMed ID: 6753514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of oral 5-HTP administration on 5-HTP and 5-HT immunoreactivity in monoaminergic brain regions of rats.
    Lynn-Bullock CP; Welshhans K; Pallas SL; Katz PS
    J Chem Neuroanat; 2004 May; 27(2):129-38. PubMed ID: 15121217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of l-5-hydroxytryptophan on brain monoamine metabolism and evaluation of its clinical effect in depressed patients.
    Takahashi S; Kondo H; Kato N
    J Psychiatr Res; 1975 Nov; 12(3):177-87. PubMed ID: 1081591
    [No Abstract]   [Full Text] [Related]  

  • 9. Serotonergic disturbances in autistic disorder: L-5-hydroxytryptophan administration to autistic youngsters increases the blood concentrations of serotonin in patients but not in controls.
    Croonenberghs J; Verkerk R; Scharpe S; Deboutte D; Maes M
    Life Sci; 2005 Mar; 76(19):2171-83. PubMed ID: 15733932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The indoleamine hypothesis of depression: an overview and pilot study.
    Zarcone VP; Berger PA; Brodie KH; Sack R; Barchas JD
    Dis Nerv Syst; 1977 Aug; 38(8):646-53. PubMed ID: 328245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central serotonin deficiency--a factor which increases depression vulnerability?
    van Praag HM; de Haan S
    Acta Psychiatr Scand Suppl; 1980; 280():89-96. PubMed ID: 6157306
    [No Abstract]   [Full Text] [Related]  

  • 12. Measurement of 5-hydroxyindole compounds during L-5-HTP treatment in depressed patients.
    Takahashi S; Takahashi R; Masumura I; Miike A
    Folia Psychiatr Neurol Jpn; 1976; 30(4):461-73. PubMed ID: 1087913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In search of the mode of action of antidepressants. 5-HTP/tyrosine mixtures in depressions.
    van Praag HM
    Neuropharmacology; 1983 Mar; 22(3 Spec No):433-40. PubMed ID: 6304561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Hydroxytryptophan-induced cortisol response and CSF 5-HIAA in depressed patients.
    Koyama T; Lowy MT; Meltzer HY
    Am J Psychiatry; 1987 Mar; 144(3):334-7. PubMed ID: 2435178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of 5-hydroxyindole compounds during L-5-HTP treatment in depressed patients.
    Takahashi S; Takahashi R; Masumura I; Miike A
    Folia Psychiatr Neurol Jpn; 1976; 30(4):463-73. PubMed ID: 1088138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central monoamine metabolism in depressions. I. Serotonin and related compounds.
    van Praag HM
    Compr Psychiatry; 1980; 21(1):30-43. PubMed ID: 6153593
    [No Abstract]   [Full Text] [Related]  

  • 17. L-5-hydroxytryptophan. Correlation between anticonvulsant effect and increases in levels of 5-hydroxyindoles in plasma and brain.
    Löscher W; Pagliusi SR; Müller F
    Neuropharmacology; 1984 Sep; 23(9):1041-8. PubMed ID: 6083501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotoninergic dysfunction in the 47, XYY syndrome.
    Bioulac B; Benezech M; Renaud B; Noel B; Roche D
    Biol Psychiatry; 1980 Dec; 15(6):917-23. PubMed ID: 6161648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic indications for serotonin-potentiating compounds: a hypothesis.
    van Praag HM; Kahn R; Asnis GM; Lemus CZ; Brown SL
    Biol Psychiatry; 1987 Feb; 22(2):205-12. PubMed ID: 2434148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of 5-hydroxytryptophan in the isolated perfused rat lung.
    Ben-Harari RR; Parent Ermini A; Kleinerman J
    Pharmacology; 1990; 41(5):272-9. PubMed ID: 1709288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.